Eisai Announced That It Has Entered Into An Agreement With The National Cancer Centre To Collaborate On Investigator-Initiated Clinical Research For The Ezh2 Inhibitor Tazemetostat Hydrobromide (Generic Name, Product Name
Found this useful? Share it with your team.
